We are live on ! Find out more

Baxter International

BAX

Market cap $12.1B

23.49 USD

+0.12

0.51%

At close Updated Sep 28, 4:00 PM EDT

Pre-market

After hours

23.40

-0.09

0.38%

1 day

0.51%

5 days

1.21%

1 month

-10.1%

3 months

6.68%

6 months

48.67%

Year to date

20.46%

1 year

4.96%

5 years

-70.9%

10 years

-50.98%

About: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Employees: 37,500

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 47.6%

Neutral 42.9%

Negative 9.5%

Zacks Investment Research

Here's Why You Should Retain Baxter Stock in Your Portfolio for Now

BAX's portfolio reset and growth in connected care and advanced surgery support prospects, but margins, Novum IQ and China pricing remain risks.

Here's Why You Should Retain Baxter Stock in Your Portfolio for Now

Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Baxter International Inc. (BAX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Zacks Investment Research

BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure

Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.

BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure

Baxter Appoints John Rogers Chief Financial Officer

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026. “John is a proven global finance executive with extensive operational expertise and a successful track record leading complex transformation initiatives,” said Hider. “He is an ideal fit for.

Baxter Appoints John Rogers Chief Financial Officer

Baxter Announces Pricing for Its Upsized Cash Tender Offers

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the pricing terms for its previously announced cash tender offers (each, an “Offer” and collectively, the “Offers”) of the Company's validly tendered (and not validly withdrawn) notes set forth below (the “Notes”) using a “waterfall” methodology under which the Company will accept the Notes in order of their respective acceptance priority levels noted in the table below (the “Accep.

Baxter Announces Pricing for Its Upsized Cash Tender Offers

Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the early results of its previously announced cash tender offers (each, an “Offer” and collectively, the “Offers”) for its validly tendered (and not validly withdrawn) notes set forth below (collectively, the “Notes”). The Offers are being made pursuant to an Offer to Purchase, dated Aug. 4, 2026 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), whi.

Baxter Announces Early Tender Results and Upsizing of Previously Announced Cash Tender Offers

Baxter Announces Cash Tender Offers

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced that it has commenced cash tender offers (each, an “Offer” and collectively, the “Offers”) for the maximum principal amount of validly tendered (and not validly withdrawn) notes set forth below (collectively, the “Notes”), such that the aggregate purchase price, not including accrued and unpaid interest, payable in respect of such Notes will not exceed $500 million. The terms and c.

Baxter Announces Cash Tender Offers

Baxter International: The Gains Can Continue, But Should Slow

Baxter International has shown early signs of a turnaround, with improving execution and raised revenue guidance supporting cautious optimism. BAX's valuation has expanded from distressed levels, now trading at ~13x earnings and ~9.5x EV/EBITDA, yet remains attractive if growth continues. Management's focus on operational improvements, cost savings, and a conservative outlook suggests potential for further upside if EPS growth materializes.

Baxter International: The Gains Can Continue, But Should Slow

The Motley Fool

Why Baxter International Stock Skyrocketed by 19% This Week

It scored double beats on analyst estimates. It also lifted its guidance on both the top and bottom lines.

Why Baxter International Stock Skyrocketed by 19% This Week

Zacks Investment Research

BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract

Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.

BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract

See News Rankings

Price charts implemented using Lightweight Charts™